Quick Answer
Immix Biopharma, Inc. reported Operating Income Loss of -$29.96 million for the year ending 2025.
- Immix Biopharma, Inc. showed a decrease of -32.1% in Operating Income Loss from 2024 to 2025.
- This data is from Immix Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$162.5 thousand | Q2 2021: -$243.2 thousand | Q3 2021: -$348.0 thousand | Q1 2022: -$1.33 million | Q2 2022: -$1.56 million | Q3 2022: -$1.53 million | Q1 2023: -$2.52 million | Q2 2023: -$3.72 million | Q3 2023: -$4.52 million | Q1 2024: -$5.59 million | Q2 2024: -$4.70 million | Q3 2024: -$7.39 million | Q1 2025: -$4.68 million | Q2 2025: -$6.72 million | Q3 2025: -$7.66 million.
- Over the full 6 years of available data (2020 to 2025), Immix Biopharma, Inc.'s Operating Income Loss has declined by 6,500.5%.
- Historical annual values: Fiscal year 2025: -$29.96 million | Fiscal year 2024: -$22.67 million | Fiscal year 2023: -$16.14 million | Fiscal year 2022: -$8.22 million | Fiscal year 2021: -$1.35 million | Fiscal year 2020: -$453.9 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: